


wherein R is n-butyl, n-propyl, benzyl, (C₁-C₁₂) alkyl, (C₇-C₁₈) aralkyl, (C₆-C₁₈) aryl, (C₁-C₁₂) alkenyl, (C₇-C₁₈) aralkenyl, (C₁-C₁₂) alkylether, and X are independently cyclic peptide loops of the general structure:



wherein R₁, R₂, R₃, and R₄ are each amino acid side chains that define a tetrapeptide sequence, wherein said tetrapeptide is covalently attached at the amino and carboxy termini of said tetrapeptide to a 3-aminomethyl-5-aminobenzamide linking group, and wherein said tetrapeptide sequence is selected from the group consisting of GDFD (SEQ ID NO. 1), GDDD (SEQ ID NO. 2), D-ADGD (SEQ ID NO. 3), GDLD (SEQ ID NO. 4), GDAD (SEQ ID NO. 5), GDGY (SEQ ID NO. 6), ADGD (SEQ ID NO. 7), GDSD (SEQ ID NO. 8), GKGF (SEQ ID NO. 9), GK GK (SEQ ID NO. 10), GDND (SEQ ID NO. 11), PDGD (SEQ ID NO. 12), GDDG (SEQ ID NO. 13), and GDDY (SEQ ID NO. 14).

Claim 5 (amended):

The compound of claim 4, in which said growth factor is a platelet derived growth factor, and wherein said tetrapeptide sequence is GDGY (SEQ ID NO. 6).

Claim 15 (amended):

The compound of claim 1 wherein said growth factor is vascular endothelial growth factor and wherein said tetrapeptide sequence is GKGK (SEQ ID NO. 10), GDGY, or functionally related derivatives thereof.

Claim 16 (amended):

615 The compound of claim wherein said growth factor is acidic fibroblast growth factor and wherein said tetrapeptide sequence is GDDD (SEQ ID NO. 2), GKGK (SEQ ID NO. 10), GDDG (SEQ ID NO. 13), GDGY (SEQ ID NO. 6), or functionally related derivatives thereof.

Claim 17 (amended):

The compound of claim 1 wherein said growth factor is insulin-like growth factor-1 and wherein said tetrapeptide sequence is GDDG (SEQ ID NO. 13) or functionally related derivatives thereof.